Hepatocellular Carcinoma | Specialty

Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC

February 3rd 2025

Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

January 27th 2025

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC

January 25th 2025

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Frontline Nivolumab/Ipilimumab Prolongs OS in Unresectable HCC

January 24th 2025

Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.

FDA Grants Orphan Drug Designation to Amezalpat for Advanced HCC

January 9th 2025

The FDA has granted orphan drug designation for the treatment of patients with hepatocellular carcinoma.

Dr Strickler on the Development of Telisotuzumab Adizutecan in MET-Amplified Gastric Cancer

January 6th 2025

John H. Strickler, MD, discusses the rationale for developing telisotuzumab adizutecan in MET gene–amplified advanced gastric cancer.

Patient Factors Drive IO Combination Selection in Unresectable HCC

January 5th 2025

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

November 26th 2024

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

November 25th 2024

Alan P. Venook, MD, highlights notable NCCN guideline updates in HCC, considerations for implementing the changes in the clinic, and next steps in HCC.

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

November 21st 2024

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC

November 19th 2024

Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Building Upon Approved Combination Regimens in Unresectable HCC

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.

The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC

October 25th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

October 25th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

October 21st 2024

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.

Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC

October 7th 2024

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC

September 23rd 2024

An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC

September 16th 2024

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC

September 14th 2024

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.